US govt ponders "open access" to research

12 November 2007

A debate in the USA over whether government-funded research into health-related issues should be made freely available to taxpayers is moving into the Democratic party-controlled Congress. Supporters of the case for reform argue that the National Institutes of Health is paid for by taxpayers and that it ought to be a condition of receiving research grants that the product will be made available to all. Opponents are mostly in the specialist medical journal publishing business.

A coalition of patient advocacy groups and libraries has succeeded in getting their position taken up in the legislature, with amendments incorporated in the latest Health and Human Services funding bill.

Heather Joseph, executive director of the Washington DC-based Scholarly Publishing and Academic Resources Coalition, told the Washington Post that most journals carry research that is not funded by the NIH, so the effect on subscriptions need not be critical. The Public Library of Science, for example, has published, since October 2003, a peer-reviewed print and on-line scientific journal, entitled PLoS Biology, and has since launched six more similar publications.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight